Lee Ainslie's NVO Position Overview
Lee Ainslie (via Maverick Capital LTD) currently holds 2.08 M shares of Novo Nordisk A/S (NVO) worth $76.44 M, representing 0.88% of the portfolio. First purchased in 2020-Q3, this medium-term investment has been held for 11 quarters.
Based on 13F filings, Lee Ainslie has maintained a strategic position in NVO, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2026, adding 2.08 M shares. Largest reduction occurred in Q4 2020, reducing 12,550 shares.
Analysis based on 13F filings available since 2013 Q2
Lee Ainslie's Novo Nordisk A/S (NVO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Novo Nordisk A/S (NVO) Trades by Lee Ainslie
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +2.08 M | New Buy | 2.08 M | $36.75 |
| Q3 2024 | -7,849 | Sold Out | 0 | $0.00 |
| Q2 2024 | +5,744 | Add 272.87% | 7,849 | $142.74 |
| Q1 2024 | +2,105 | New Buy | 2,105 | $128.40 |
| Q2 2023 | -4,312 | Sold Out | 0 | $0.00 |
| Q1 2023 | -296 | Reduce 6.42% | 4,312 | $79.57 |
| Q4 2022 | -342 | Reduce 6.91% | 4,608 | $67.67 |
| Q3 2022 | +4,950 | New Buy | 4,950 | $49.90 |
| Q1 2021 | -5,316 | Sold Out | 0 | $0.00 |
| Q4 2020 | -12,550 | Reduce 70.25% | 5,316 | $34.99 |
| Q3 2020 | +17,866 | New Buy | 17,866 | $34.70 |
Lee Ainslie's Novo Nordisk A/S Investment FAQs
Lee Ainslie first purchased Novo Nordisk A/S (NVO) in Q3 2020, acquiring 17,866 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Lee Ainslie has held Novo Nordisk A/S (NVO) for 11 quarters since Q3 2020.
Lee Ainslie's largest addition to Novo Nordisk A/S (NVO) was in Q1 2026, adding 2,080,121 shares worth $76.44 M.
According to the latest 13F filing for Q1 2026, Lee Ainslie's firm, Maverick Capital LTD, owns 2,080,121 shares of Novo Nordisk A/S (NVO), valued at approximately $76.44 M.
As of the Q1 2026 filing, Novo Nordisk A/S (NVO) represents approximately 0.88% of Lee Ainslie's publicly disclosed stock portfolio, making it one of their key holdings.
Lee Ainslie's peak holding in Novo Nordisk A/S (NVO) was 2,080,121 shares, as reported at the end of Q1 2026.